Skip to main content

A roundup of some of the North American equities making moves in both directions today

On the rise

Shares of Canopy Growth Corp. (WEED-T) were up over 14 per cent on Monday after announcing Constellation Brands Inc. (STZ-N) finance head David Klein will take over in January as chief executive officer of the pot producer.

Mr. Klein was appointed Canopy chairman in October after Constellation booked a $430 million net loss related to the company. He replaces company co-CEO Mark Zekulin who took over the top job from founder Bruce Linton in July.

Story continues below advertisement

Mr. Linton had said that he was fired from the top job, days after Constellation expressed its disappointment over Canopy’s 2018 results.

Shares of Constellation were down 1.3 per cent in New York.

See also: Canopy shares fall as Constellation says it doesn’t intend to make further investments

Medicenna Therapeutics Corp. (MDNA-T), a Toronto-based clinical stage immuno-oncology company, jumped 20.7 per cent after announcing plans to present the results from the latest trial for its MDNA55 drug for the treatment of recurrent glioblastoma at a conference in Boston on Wednesday.

The company is also set for a presentation at the 12th Annual LD Micro Main Event Investor Conference in Los Angeles on Tuesday.

On the decline

Hudson’s Bay Co. (HBC-T) slid 1 per cent after its special committee said on Monday it was disappointed with proxy adviser Institutional Shareholder Services’ recommendation to vote against the takeover bid by a consortium led by the retailer’s chairman, Richard Baker.

“We are disappointed by the ISS recommendation and the errors and flawed rationale of ISS,” said David Leith, chair of the retailer’s special committee that negotiated the deal with Baker’s group.

Story continues below advertisement

ISS last week recommended shareholders to vote against the Baker-led consortium’s $1.9-billion deal, which was topped by Toronto-based buyout firm Catalyst Capital Group Inc.

The special committee in November had rejected Catalyst’s offer saying it was not “superior”.

See also: ISS hands win to Catalyst on eve of HBC hearing

Merck & Co. (MRK-N) were lower by 0.2 per cent after it said on Monday it would buy cancer drug developer ArQule Inc. (ARQL-Q) in a US$2.7-billion all-cash deal, bolstering its oncology franchise with the smaller rival’s lead drug that is being tested as a treatment for blood cancer.

The offer of US$20 per share for ArQule is more than double its closing price on Friday.

The deal, expected to close early in the first quarter of 2020, would give Merck access to ArQule’s experimental treatment ARQ 531, a precision medicine that tailors treatment to a patient’s genetic profile.

Story continues below advertisement

Massachusetts-based ArQule jumped 103.7 per cent.

3M Co. (MMM-N) slipped 1 per cent after an equity analyst at Citi downgraded its stock to “neutral” from a “buy” recommendation.

Andrew Kaplowitz said: “While we think MMM’s shorter-cycle end markets could be closer to a bottom and execution seems poised to improve, growing PFAS-litigation related risks could be a lingering overhang that prevents a re-rating to its former premium multiple.”

With files from staff and wires

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies